Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

Benzinga.com  December 12, 2016

Mid-Morning Market Update: Markets Open Mixed; Crude Oil Hits 17-Month High On OPEC Commitments

Benzinga.com  December 12, 2016

Alexion Management Changes Overshadow Potentially Positive Audit Results

Benzinga.com  December 12, 2016

Alexion’s Board of Directors Announces New Leadership Appointments

Business Wire December 12, 2016

Why Stocks Move When Execs Cancel Presentation Appearances

Benzinga.com  December 7, 2016

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alexion Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm

Business Wire December 7, 2016

8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting

Benzinga.com  December 6, 2016

New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Business Wire December 4, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALXN

GlobeNewswire December 2, 2016

Lifshitz & Miller Law Firm Announces Investigation of Alexion Pharmaceuticals, Inc., Blue Nile, Inc., Hill International, Inc., InfuSystem Holdings Inc., Rent-A-Center, Inc., Treehouse Foods, Inc. and Viking Investments Group, Inc.

PR Newswire December 1, 2016

Watch These 7 Huge Call Purchases In Wednesday Trade

Benzinga.com  November 30, 2016

Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares Tumble After Failed Drug Trial

Benzinga.com  November 29, 2016

Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Benzinga.com  November 29, 2016

Alexion to Present at the Citi 2016 Global Healthcare Conference

Business Wire November 29, 2016

Lawsuit for Investors in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares announced by Shareholders Foundation

GlobeNewswire November 29, 2016

The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble

Benzinga.com  November 29, 2016

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline – ALXN

GlobeNewswire November 27, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALXN

PR Newswire November 25, 2016

ALXN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017

GlobeNewswire November 25, 2016

Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action

Business Wire November 22, 2016